PubMed ID:
16923411
Public Release Type:
Journal
Publication Year: 2006
Affiliation: Rhode Island Hospital, Providence, RI 02903, USA.
DOI:
https://doi.org/10.1016/j.ahj.2006.03.004
Authors:
Bostom AG,
Carpenter MA,
FAVORIT Investigators,
Hunsicker LG,
Jacques PF,
Kusek JW,
Levey AS,
McKenney J,
Pfeffer MA
Studies:
Folic Acid for Vascular Outcome Reduction in Transplantation Trial
Patients with chronic kidney disease, including kidney transplant recipients, are at high risk for cardiovascular disease (CVD). In addition to the constellation of traditional CVD risk factors in chronic kidney disease, elevated total homocysteine (tHcy) is notably more prevalent among the general population. The Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial is designed to evaluate whether lowering tHcy using vitamin supplementation reduces CVD events in renal transplant recipients.